The Impact Of Ceftazidime-Avibactam Utilization In Hospital Setting

Ceftazidime-avibactam (CZA) represents a novel therapeutic approach for combating infections caused by multidrug-resistant Gram-negative bacteria. With the rise of antimicrobial resistance posing a significant challenge in hospital settings, this study aims to evaluate the utilization of CZA in hospitals and its subsequent outcomes. A retrospective study was conducted, analyzing data from medical records of patients who received CZA treatment in a large tertiary care hospital over a six-month period. Demographic information, clinical characteristics, Charlson comorbidity scale, PITT bacteremia score, microbiological data, treatment regimens, and outcomes were collected and analyzed. Descriptive statistics were used to summarize patient characteristics and outcomes. A total of 104 patients received ceftazidime avibactam, with a mean age of 57years. The most common indication is given as definite63.46%(66) and 36.53% (38) were received as empirical. The mean of 6days. In this 65.38%(68) patients were improved &discharged and declared patients were 34.61%(36),as shown in the table below. In conclusion, antimicrobial stewardship accepted in only 14.42%, empirical employment of ceftazidime-avibactam in hospitals faces significant drawbacks. Issues including escalating resistance, sparse clinical evidence, and economic burdens raise doubts about its utility. Prudent consideration of alternatives and continued monitoring are essential to navigate uncertainties surrounding its effectiveness in tackling multidrug-resistant infections.